Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 04, 2024 (filed on Jan 04, 2024)Insider Name:Atkins Michael B.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Jan 04, 2024 (filed on Jan 04, 2024)Insider Name:Atkins Michael B.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Trost Timothy W.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Lubman EllenOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:131,900Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Isaacs RandiOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Karunatilake ChulaniOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Seidel-Dugan CynthiaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Hicklin Daniel JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:435,000Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-13,200Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Morrison BriggsOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,200Price:--
Filings by filing date
-
Jan 04, 2024 (filed on Jan 04, 2024)Insider Name:Atkins Michael B.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Jan 04, 2024 (filed on Jan 04, 2024)Insider Name:Atkins Michael B.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Trost Timothy W.Ownership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Lubman EllenOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:131,900Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Isaacs RandiOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Karunatilake ChulaniOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Seidel-Dugan CynthiaOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:150,000Price:--
-
Jan 02, 2024 (filed on Jan 04, 2024)Insider Name:Hicklin Daniel JOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:435,000Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Ra Capital Management, L.P.Ownership Type:Indirect OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:-13,200Price:--
-
Jun 21, 2023 (filed on Jun 23, 2023)Insider Name:Morrison BriggsOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:13,200Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 200 Talcott Avenue, 2Nd Floor WATERTOWN MA 02472 |
Tel: | N/A |
Website: | https://werewolftx.com |
IR: | See website |
Key People | ||
Daniel J. Hicklin President, Chief Executive Officer, Director | Timothy W. Trost Chief Financial Officer, Treasurer | Reid J. Leonard Chief Operating Officer |
Chulani Karunatilake Chief Technology Officer | Randi Isaacs Chief Medical Officer | Ellen A. Lubman Chief Business Officer |
Business Overview |
Werewolf Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Its product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with pembrolizumab in multiple solid tumor types. WTX-330 is in development as a single agent in metastatic solid tumors and non-Hodgkin lymphoma. Its pipeline also includes JZP898 and WTX-712. |
Financial Overview |
For the fiscal year ended 31 December 2023, Werewolf Therapeutics Inc revenues increased 22% to $19.9M. Net loss decreased 31% to $37.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development - Balancing val decrease of 25% to $37.8M (expense), Interest income increase from $1.9M to $7.4M (income). |
Employees: | 47 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $184.14M as of Dec 31, 2023 |
Annual revenue (TTM): | $19.94M as of Dec 31, 2023 |
EBITDA (TTM): | -$38.74M as of Dec 31, 2023 |
Net annual income (TTM): | -$37.37M as of Dec 31, 2023 |
Free cash flow (TTM): | -$33.38M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 43,347,363 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |